Senopsys Launches CRO Service

Senopsys LLC, a specialty services company that partners with pharmaceutical, biopharmaceutical and drug delivery companies and their CROs to improve the palatability of pharmaceuticals, has been launched.

Senopsys uses proprietary sensory assessment tools to identify the critical sensory attributes of drug substances, quantify taste masking challenges, measure the flavor quality or palatability of drug prototypes and competing products, and develop target sensory profiles that result in patient-acceptable pharmaceuticals. The company also works with drug developers to assess dosage forms for specific drug substances and develop new formulation systems for investigational and approved drugs.

“The simple truth is if patients don’t like a medication, they just won’t take it, which can have far-reaching implications on patient health and the widespread acceptance of a drug product,” said Jeff Worthington, founder of Senopsys. “Many will point to a product’s flavor as the key determinant of patient acceptance; but a drug’s palatability is much more complicated than its flavor. The key to developing palatable pharmaceuticals lies beneath the surface and includes factors such as balancing the four basic tastes—sweet, sour, salty and bitter—building blend and body, extending the aftertaste duration, and adding beneficial mouth feel factors.”

“Unfortunately, few drug developers have the expertise to effectively evaluate or optimize these factors, which can have such a significant impact on acceptability and sales,” Worthington continued. “This is where Senopsys steps in. We help reduce technical and market risks associated with a product’s aesthetics so that developers can concentrate on other technical aspects of clinical and commercial development.”

Senopsys is an independent and objective partner that does not license technology or sell ingredients. The company aims to provide custom formulations that meet the needs of diverse patient populations.